230 related articles for article (PubMed ID: 26415995)
1. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.
Bar J; Ding K; Zhao H; Han L; Laurie SA; Seymour L; Addison CL; Shepherd FA; Goss GD; Dimitroulakos J; Bradbury PA
Clin Lung Cancer; 2015 Nov; 16(6):e189-201. PubMed ID: 26081815
[TBL] [Abstract][Full Text] [Related]
3. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.
Addison CL; Ding K; Zhao H; Le Maître A; Goss GD; Seymour L; Tsao MS; Shepherd FA; Bradbury PA
J Clin Oncol; 2010 Dec; 28(36):5247-56. PubMed ID: 21079146
[TBL] [Abstract][Full Text] [Related]
4. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
Nikolinakos PG; Altorki N; Yankelevitz D; Tran HT; Yan S; Rajagopalan D; Bordogna W; Ottesen LH; Heymach JV
Cancer Res; 2010 Mar; 70(6):2171-9. PubMed ID: 20215520
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
Jürgensmeier JM; Schmoll HJ; Robertson JD; Brooks L; Taboada M; Morgan SR; Wilson D; Hoff PM
Br J Cancer; 2013 Apr; 108(6):1316-23. PubMed ID: 23449351
[TBL] [Abstract][Full Text] [Related]
6. Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.
Addison CL; Pond GR; Cochrane B; Zhao H; Chia SK; Levine MN; Clemons M
J Bone Oncol; 2015 Jun; 4(2):47-53. PubMed ID: 26579488
[TBL] [Abstract][Full Text] [Related]
7. Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.
Pommier AJ; Shaw R; Spencer SK; Morgan SR; Hoff PM; Robertson JD; Barry ST; Jürgensmeier JM
Br J Cancer; 2014 Oct; 111(8):1590-604. PubMed ID: 25121956
[TBL] [Abstract][Full Text] [Related]
8. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
Laurie SA; Solomon BJ; Seymour L; Ellis PM; Goss GD; Shepherd FA; Boyer MJ; Arnold AM; Clingan P; Laberge F; Fenton D; Hirsh V; Zukin M; Stockler MR; Lee CW; Chen EX; Montenegro A; Ding K; Bradbury PA
Eur J Cancer; 2014 Mar; 50(4):706-12. PubMed ID: 24360368
[TBL] [Abstract][Full Text] [Related]
9. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Goodwin R; Ding K; Seymour L; LeMaître A; Arnold A; Shepherd FA; Dediu M; Ciuleanu T; Fenton D; Zukin M; Walde D; Laberge F; Vincent M; Ellis PM; Laurie SA;
Ann Oncol; 2010 Nov; 21(11):2220-2226. PubMed ID: 20427348
[TBL] [Abstract][Full Text] [Related]
10. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
Goss GD; Arnold A; Shepherd FA; Dediu M; Ciuleanu TE; Fenton D; Zukin M; Walde D; Laberge F; Vincent MD; Ellis PM; Laurie SA; Ding K; Frymire E; Gauthier I; Leighl NB; Ho C; Noble J; Lee CW; Seymour L
J Clin Oncol; 2010 Jan; 28(1):49-55. PubMed ID: 19917841
[TBL] [Abstract][Full Text] [Related]
12. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.
Jantus-Lewintre E; Sanmartín E; Sirera R; Blasco A; Sanchez JJ; Tarón M; Rosell R; Camps C
Lung Cancer; 2011 Nov; 74(2):326-31. PubMed ID: 21481963
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C
Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649
[TBL] [Abstract][Full Text] [Related]
14. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC.
Blumenschein GR; Reck M; Fossella F; Stewart DJ; Lathia C; Peña C
Cancer Biomark; 2011-2012; 10(6):287-98. PubMed ID: 22820084
[TBL] [Abstract][Full Text] [Related]
15. Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.
Li J; Hu YM; Du YJ; Zhu LR; Qian H; Wu Y; Shi WL
BMC Cancer; 2014 Nov; 14():848. PubMed ID: 25410981
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.
Zhou C; Taylor S; Tugwood J; Simpson K; Jayson GC; Symonds P; Paul J; Davidson S; Carty K; McCartney E; Rai D; Dive C; West C
Br J Clin Pharmacol; 2019 Aug; 85(8):1781-1789. PubMed ID: 30980733
[TBL] [Abstract][Full Text] [Related]
17. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
18. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Hanrahan EO; Lin HY; Kim ES; Yan S; Du DZ; McKee KS; Tran HT; Lee JJ; Ryan AJ; Langmuir P; Johnson BE; Heymach JV
J Clin Oncol; 2010 Jan; 28(2):193-201. PubMed ID: 19949019
[TBL] [Abstract][Full Text] [Related]
19. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Hanrahan EO; Ryan AJ; Mann H; Kennedy SJ; Langmuir P; Natale RB; Herbst RS; Johnson BE; Heymach JV
Clin Cancer Res; 2009 May; 15(10):3600-9. PubMed ID: 19447868
[TBL] [Abstract][Full Text] [Related]
20. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]